HC Deb 10 April 2002 vol 383 cc426-7W
Mr. Burns

To ask the Secretary of State for Health what estimate he has made of the cost per annum of Tamoxifen for women who do not have breast cancer but are considered to be at high risk. [46722]

Yvette Cooper

Tamoxifen is licensed for the treatment of breast cancer and the treatment of anovulatory infertility.

Tamoxifen is not licensed for the prevention of breast cancer in women who do not have breast cancer. A large international research trial is currently investigating whether tamoxifen can prevent cancer in healthy women who are considered to be at high risk. When the full trial results are published we will consider what action may be appropriate and estimate the cost implications.